Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
September 20, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an...
Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences
September 19, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit...
Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference
August 29, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates
August 01, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results
July 25, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO , July 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2018, after the...
Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
July 02, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor emricasan,...
Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates
May 02, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced...
Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension
April 30, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan,...
Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results
April 25, 2018 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2018, after the...
Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo
April 18, 2018 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 18, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...